Clinical Trial Detail

NCT ID NCT02949219
Title Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

jejunal adenocarcinoma

duodenum adenocarcinoma

ileum cancer

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.